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ABSTRACT
This review looks at the strategies that may help
to reduce the risk of sudden unexpected death in
epilepsy beyond that of trying to achieve seizure
cessation, which is not possible for up to 30% of
patients with epilepsy. These strategies include
seizure safety checklists, mobile phone
technology, telehealth and various devices
currently available or in development. We
highlight interventions where there is evidence of
benefit, and draw attention for the need both to
involve patients with epilepsy in risk reduction
and to improve communication with those at
risk.
INTRODUCTION
There is nothing so tragic as a life need-
lessly lost.
The consequences of epilepsy are mani-
fold. Aside from the effects it has on
peoples’ lives as a result of social conse-
quences (employment, driving, schooling
and sporting) and medication (side
effects, contraception and pregnancy),
there are medical consequences with the
risk of injuries, cognitive problems and
ultimately premature death. Epilepsy is
the fifth highest cause of life years lost,
second only to stroke as a neurological
disorder, and the most common cause of
death in younger people.1–3
The National Sentinel Audit of
epilepsy-related deaths in 2002 recorded
1200 epilepsy-related deaths annually in
the UK, of which 42% were felt to be
avoidable.1 In 2013 there were 1187
deaths attributed to epilepsy in England
and Wales, suggesting little progress in
attempting to reduce the risk.4 Sudden
unexpected death in epilepsy (SUDEP),
defined as death not due to accidents or
witnessed seizures, peaks in young adults;
about 1% of young men with epilepsy
die before the age of 30 years.5
Strategies to reduce the risk of SUDEP
must involve not only people with
epilepsy but also their general practi-
tioners. General practitioners have the
most medical contact with people with
epilepsy, not just for their epilepsy but
also for other conditions that may also
influence risk, such as depression and
substance misuse.6 7 The UK’s National
Institute for Health and Care Excellence
epilepsy guidelines from 2004 to 2012
clearly state that the risk of death in epi-
lepsy, in particular SUDEP, should be dis-
cussed as a priority at the time of
diagnosis.8 9 Its equivalent in Scotland,
the Scottish Intercollegiate Guidelines
Network epilepsy guidelines 2015, sug-
gests discussion about SUDEP at an
‘appropriate time’.10 Despite this risk,
there is a tacit avoidance of discussing the
risk of death both in primary and second-
ary care, while the patient organisations
and SUDEP Action (formerly Epilepsy
Bereaved) vociferously support the
patients’ view that such risks should be
made transparent (see box 1). This article
sets out strategies that may help clinicians
to improve person-centred communica-
tion when dealing with epilepsy, to
reduce this risk.11
INITIAL MEASURES TO REDUCE RISK
Reducing seizure frequency, particularly
tonic–clonic seizures, may seem self-
evident as a primary goal, but until a
recent meta-analysis of randomised con-
trolled trials there was little evidence that
reducing seizures did reduce SUDEP
risk.12 Achieving this requires a cohesive
approach from clinicians and teams with
expertise in epilepsy. For that reason, a
diagnosis of epilepsy should only be
made by someone with an interest in epi-
lepsy, be that a general neurologist or an
epileptologist. The initial management
should use a team approach, with the epi-
lepsy nurse specialist (if available) being
central. Information provided sensitively
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at an early stage empowers people with epilepsy, and
we propose an early discussion about SUDEP, usually
at the first follow-up after confirmation of diagnosis,
as raising this issue at the diagnostic stage can be too
difficult for some. In our practice, most people with
epilepsy (and their families or carers) welcome the dis-
cussion of SUDEP, and find that this helps the discus-
sion around many aspects of management.13
The choice of antiepileptic medication is important,
as some may worsen certain epilepsies (eg, carbamaze-
pine and myoclonic epilepsies). While up to 70% of
patients become seizure free on their first choice for
monotherapy, it is important to pay heed to reported
side effects, not least because of the risk of non-
concordance. Thirty per cent of people with long-
term conditions in general do not take their medica-
tions regularly; epilepsy is no exception.14
Women in their fertile years require special con-
sideration, and antiepileptic drug interactions with
hormonal contraception, fears about teratogenicity,
vomiting in pregnancy and blood concentration
changes all demand a proactive approach. Specific
clinics particularly linked to maternity services may
help.15
Choosing an easy dosing regimen also helps—once
daily dosing may suit some patients—and always
enquire about the ease of swallow and palatability of
medicines, since problems with these may reduce con-
cordance. In people with intellectual disability and
percutaneous endoscopic gastrostomy feeding, there
may be formulation issues that influence absorption.
When first-line treatments fail, leaving the patient
with refractory epilepsy, the clinician should consider
planned sequential monotherapy or polytherapy. In
one study, up to 16% of people whose epilepsy was
considered refractory became seizure free or signifi-
cantly improved.16 People with epilepsy often respond
positively to participation in clinical trials, audits and
studies, and centres participating in such activities
report greater patient satisfaction and better outcomes.
It is worth considering surgical interventions when
medical management fails. Resective surgery remains
the gold standard for selected people with epilepsy,
with reported seizure freedom rates of 70% for
temporal and 50% for extra-temporal procedures,
although long-term data show that seizures may
recur.17 Vagus nerve stimulation is often considered
when resective surgery is not appropriate for various
reasons, such as an unclear seizure focus, comorbid-
ities, possible cognitive risks and so on. Many people
with epilepsy prefer this option, and recent advances
in device technologies now provide automated trigger-
ing, based on the heart rate changes that may accom-
pany seizure onset.18
DISCUSSING SUDEP
Discussing SUDEP has been controversial and some
countries still advocate a paternalistic approach on a
‘need to know basis’.19 A recent court judgement in
Scotland supported the view that people with epilepsy
and their families were entitled to be provided with
such information at an early stage (see box 2 for
website links). The timing of such a discussion should
be tailored to individual needs. Sometimes an early dis-
cussion is not appropriate; for example, if there
is active psychiatric comorbidity or epilepsy has
occurred in the setting of a malignant cerebral tumour.
In patients with intellectual disability, the family and
carers usually wish to know as early as possible. In our
practice, we have this discussion using a structured
approach and aided by the SUDEP and seizure safety
checklist (box 1) at diagnosis in people with intellectual
disability, and at the first follow-up in those without.
SUDEP RISK CHECKLIST
The SUDEP and seizure safety checklist
Common sense suggests anything that reduces seizure
frequency should reduce mortality; hence improving
concordance with medication, avoiding seizure
Box 2 Useful websites
https://www.sudep.org/checklist—seizure safety checklist
https://www.sudep.org//epilepsy-self-monitor—epilepsy
self-monitor (EpSMon)
https://www.youtube.com/watch?v=e3mECsSVgHI—
EpsMon demonstration video
https://www.youtube.com/watch?v=Z9KHQvsapAc—
administering seizure safety checklist
http://www.who.int/patientsafety/safesurgery/checklist/en/
—the surgical safety checklist
http://cdrwww.who.int/patientsafety/safesurgery/
Surgical_Safety_Checklist.pdf—surgical safety checklist in
use
http://qualitysafety.bmj.com/content/early/2014/07/18/
bmjqs-2013-002772.full—patients’ views on the surgical
safety checklist
http://www.epilepsytoolkit.org.uk/—national epilepsy
toolkit
http://www.scotland-judiciary.org.uk/10/794/
Fatal-Accident-Inquiry-into-the-deaths-of-Erin-Casey-and-
Christina-Fiorre-Ilia—the Scottish fatal accident enquiry
Box 1 Quote from a patient—with permission
The patient who has epilepsy commented: “EpSMon is
just what I need to monitor my risk in between visits to
doctors. It helps me take actions at all times as it mea-
sures my own particular risks of epilepsy. It can act as a
safety net, being an excellent reminder of the importance
of taking medication correctly and seeing my GP on a
regular basis.”
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triggers and so on are all part of our routine care
plans. However, the evidence basis for this common-
sense approach derives only from retrospective
studies. While there are common themes, there is no
consensus on a standardised approach to risk
reduction.
Safety checklists now form part of routine clinical
practice, particularly in surgery where they reduce mor-
bidity and mortality; both clinicians and patient groups
support their use20 (see box 1 for website links).
Creating such lists requires a detailed assessment and
validation of the variables that contribute to risk.
There are numerous studies looking at the risk
factors for SUDEP. An in-depth review of the literature
identified 18 risk factors,7 21 leading to our develop-
ment of a safety checklist (figure 1A, B). Of the 18
factors, 11 were potentially modifiable, particularly
non-adherence to antiepileptic medications, substance
misuse, mood disorders and sleep disruption (see
https://www.sudep.org/checklist to register, see train-
ing videos and access a copy). There is no absolute
risk assigned to each item, nor to the sum of the
items, but completing the list allows a discussion
around risk modification. Detailed analysis and strati-
fication of the risk factors show that some are more
significant than others.22 Despite initial fears that
raising the issues might cause unnecessary alarm,
patients tend to receive it positively13 and using the
checklist can modify behaviours.23
The charity ‘SUDEP Action’ launched the SUDEP
and seizure safety checklist in the UK in 2015. There
are 19 questions covering SUDEP and seizure safety
risk, updated from evidence on SUDEP and fatality
risk in epilepsy, and a question about the use of emer-
gency services. Administering the checklist takes about
10 min, although discussion around the identified
risks takes longer. Partners/carers of people with epi-
lepsy are often more positive than patients about the
checklist—after all, they watch the seizures and pick
up the pieces afterwards.
While a clinic-led safety checklist is a step forward,
it requires the patient to attend; hence we need an
empowerment tool in the community. Lack of engage-
ment with services is an identified risk. In 90% of
SUDEP cases, there was deteriorating seizure control
in the 3–6 months before death, and most had not
had an epilepsy review for at least a year.24 Thus,
while simple strategies can reduce or better manage
risk, these interventions also need to be positioned
either in primary care or with the patients themselves.
TELEHEALTH
Telehealth projects are well established in other disci-
plines, such as cardiac failure and chronic obstructive
pulmonary disease. Such systems have now been piloted
in epilepsy in a primary care setting using a telehealth
non-clinical professional to contact people perceived to
be at high risk every 3 months. Seventeen per cent of
patients had an intervention that would otherwise have
not happened.23 This programme is potentially cheaper
than medically led interventions, seems acceptable to
patients and general practitioners, has not resulted in
increased referrals to secondary care and is now being
developed over a larger primary care population.
MOBILE EHEALTH (SMARTPHONES, etc)
The use of technology is often overlooked in medi-
cine. The at-risk age group for SUDEP is smartphone
savvy, and this seems an obvious aid to communica-
tion and risk assessment. There is now a mobile
phone app, epilepsy self-monitor (EpSMon) based on
the safety checklist (figure 2A, B), available free on
iPhone and Android (see box 1 for website links). It is
patient driven, and reminds the user to repeat the
assessment every 3 months. Risks are summarised
and, if present, the app suggests a review with the
general practitioner and provides relevant education.
Data are stored on a secure server along with a univer-
sity governance policy for research purposes (made
available on application to suitable research groups).
The Epilepsy Foundation (USA) is to release the app
‘EpSMon USA’ shortly, with evidence of its continued
usability and model of delivery.25 While there has
been a flood of medical apps across many conditions
in recent years—many unregulated, unevidenced and
of doubtful benefits—the involvement of the evi-
dence, users, charities and professionals in app devel-
opment has led to EpSMon and the SUDEP and
seizure safety checklist being recognised as part of the
national epilepsy toolkit (see box 1 for website links).
The press and social media showed considerable
interest in EpSMon, and the launch of the iOS
version for mobile phones featured in The Guardian
newspaper (figure 3). This type of publicity can help
to reduce the stigma of epilepsy and to spread public
awareness of its risks as a lifelong condition. It gives
patients a positive message that they can be ‘empow-
ered’ to take charge of their condition (see box 1).
Nevertheless, a barrier to the use of the apps is the
lack of awareness of risks of epilepsy, which the public
generally consider as ‘safe’. In addition, the 3-month
gap between assessments could disengage the user.
Such apps clearly need continued advertising and col-
laboration with patient groups and development of a
seizure and medication monitoring daily diary.
Certain other factors such as bias of self-reporting
are more difficult to address and felt to be a ‘neces-
sary evil’ to take advantage of patient self-
empowerment. The expectation is that with repeated
reviews and research of growing usage data this bias
could be reduced over time.
DEVICE TECHNOLOGY
A recent systemic review into available commercial
seizure detection devices showed no suitable robust
seizure detection and safety technology though some
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Figure 1 (A and B) Snapshots of sudden unexpected death in epilepsy and seizure safety checklist. The checklist is freely available in the UK. To access it, a request needs to be made by
submitting an email. If the email is from a government department or university, no further information is required and the checklist is emailed to the requester. However, if a private email
address is used (eg, john.smith@gmail.com), then a few details of who and why the checklist is being requested are asked for. There are two reasons for this: (A) The checklist risk factors are
updated each year based on reviews of evidence and contact details ensure the update is emailed to all users. (B) The contact detail allows for audit and feedback processes on issues such as
frequency of use, ease of use, barriers to implementation and so on.
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were clearly promising.26 Most available devices detect
movement and/or physiological changes that occur
before or during a seizure such as altered blood oxygen
levels, heart rate changes, electrical activity in muscles
and changes in galvanic skin resistance. Whether we
can call seizure-alert dogs a ‘device’ is debatable.
Movement sensors
These comprise a pressure sensor map placed under
the mattress or sheets to detect an abnormal
movement and absence of movement. While weight
and sleep movement adjustments can be made, seizure
detection rates are variable, with the most successful
devices picking up 89% of tonic–clonic seizures,27
although one study failed to detect any seizures.
Specificity is poor, with frequent false positives, so
disrupting sleep of both carers and patients. As with
all sensor devices for epilepsy, they also raise issues of
individual privacy. Nonetheless, these remain the most
popular among parents because of their simplicity.
Figure 2 (A and B) Epilepsy self-monitor mobile phone app—poster and flier.
Figure 3 The Guardian newspaper review—highlighting the potential impact of technology.
REVIEW
Mclean B, et al. Pract Neurol 2016;0:1–8. doi:10.1136/practneurol-2016-001392 5
 on 23 A
pril 2018 by guest. P
rotected by copyright.
http://pn.bm
j.com
/
P
ract N
eurol: first published as 10.1136/practneurol-2016-001392 on 30 N
ovem
ber 2016. D
ow
nloaded from
 
Accelerometers
These detect motion and change in velocity in two or
three dimensions. Smartphones are particularly good
for this. Sensitivity can be as high as 95%,28 but again
specificity is lower. Speed of detection in one study
was a median of 17 s with all detected within 30 s.29
The use of two accelerometers may improve nocturnal
seizure detection.
Physiological changes
Seizure onset is associated with altered autonomic
activity, including decreased skin resistance. When
combined with an accelerometer, a galvanic device
detected 94% of seizures, but with a significant false
positive rate.30
Heart rate monitors in one study were 100% sensi-
tive for tonic–clonic convulsions, and almost good for
myoclonic seizures, but attempts to refine by adding
breathing detectors or electromyographic analysis pro-
vided no advantage.
Apnoea devices combined with heart rate monitors
are attractive in theory, but studies have not yet shown
any benefits.
Electromyography
There are no devices for home use, but when com-
bined with video electroencephalogram (EEG), there
was 100% sensitivity within 30 s for tonic–clonic
convulsions. Thus, the assessment of a more suitable
device is in progress.
Video and infrared devices
Video monitoring is feasible, but has not been vali-
dated by EEG support. Infrared movement monitors
reliably correlate with carer-reported activity, which
did not necessarily confirm seizures.31 Using infrared
spectroscopy to measure blood oxygen changes failed
to detect seizures.
Seizure-alert dogs
There are numerous anecdotal reports of dogs suc-
cessfully detecting seizures, but no rigorous studies.32
Dogs may alert to the seizure itself but not to its
onset. Dogs may also react both to non-epileptic sei-
zures and epileptic seizures, and so are not specific.
One study reported seizure reduction but our group
experienced the tragedy of a patient being killed by
her dog that was responding to a seizure.
Antisuffocation pillows
These are often purchased by families, and are adver-
tised on epilepsy support websites, with one study on
carbon dioxide retention properties showing theoret-
ical benefits.33 There is also the advantage that they
are cheap and harmless.
Figure 4 (A and B) Epiwatch—iWatch and iPhone link.
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FUTURE DEVELOPMENTS
Refinements in safety checklists to provide semiquan-
tified risk stratification may become more powerful in
anticipating the risks of SUDEP.22 The future will be
in using readily available technologies with which
patients are already familiar. Self-monitoring will
increasingly use innovations in powerful devices such
as smartphones and smartwatches. ‘Embrace’, a smart-
phone self-monitoring app based on physiological
measurements (physiological stress, arousal, sleep and
physical activity), is now marketed in the USA. It has
a built-in accelerometer, gyroscope, electrodermal
activity sensor and peripheral temperature sensor and
provides a personalised insight to an individual’s activ-
ity and seizures. It links to a smartphone and claims to
detect convulsive seizures alerting others via a smart-
phone link. However, there are no available trial data
to support its claims. A miniature apnoea detection
device and respiratory monitor showed 100% sensitiv-
ity and specificity in detecting apnoeas, with a clinical
trial now planned. ‘Epiwatch’, an app for the new
iWatch developed by researchers at Johns Hopkins
Hospital in Baltimore, Maryland, USA, offers a
seizure recording and medication monitoring facility
and has the potential to be linked to seizure detection
devices (figure 4A, B).
SUMMARY
People with epilepsy need a person-centred, shared-care
approach, including early discussion of SUDEP.
Achieving seizure freedom through a careful choice of
medication and consideration of surgical interventions
is all important. Only long-term studies will determine
whether safety checklists, telehealth interventions and
mobile technologies have an impact. We have used these
approaches for several years, and have seen SUDEP in
our region fall in the intellectually disabled community
from 4–5/year to nil, and in the non-intellectually dis-
abled community from 6 to 1–2/year. How much of this
is from the checklist, and how much from increased
awareness among clinicians, the media and people with
epilepsy or from improved services in general is difficult
to determine. However, these interventions do raise the
profile of epilepsy mortality and may contribute to
enhanced awareness. Device technology is still in its
infancy, and we cannot recommend any single device
particularly as none has been shown to prevent SUDEP.
The ideal drug—one that suppresses all seizure activity
and is free from side effects—may not be developed in
our lifetime. Furthermore, clinically based interventions
will not capture those individuals at high risk.
Self-monitoring by people with epilepsy or carers
remains important, although there will still be those
whose lifestyles put them at risk. Good communication
is essential, but current services are not structured with
that in mind. Professionals can only do so much, leaving
a service gap between the epilepsy professionals, who
see a snapshot of a patient’s life, and the day-to-day
experiences of people with epilepsy. Empowering
people with epilepsy to take responsibility for their con-
dition would do much to bridge that gap.
Key points
▸ Sudden unexpected death in epilepsy (SUDEP) should
be discussed at an early stage.
▸ Seizure freedom is the most important factor in pre-
venting SUDEP; choice of medication, perseverance
with medication changes and consideration of surger-
ies are the best ways to achieve this.
▸ Safety checklists, telehealth interventions and mobile
technologies, such as epilepsy self-monitor, may
reduce the chance of SUDEP.
▸ Device technologies for seizure detection have so far
been disappointing.
▸ Patient empowerment is essential if we are to
prevent SUDEP.
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